In parallel with AI-driven efficiency claims for clinical trial monitoring, U.S. policymakers are pushing faster first-in-human trial execution through regulatory modernization initiatives, including an FDA pilot for expedited INDs. The report described a process that would use third-party reviewers and start IND submissions next year, aiming to cut friction for sponsors seeking early clinical access. The emphasis on accelerated pathway infrastructure reflects ongoing competitive pressure from other countries that have adopted more efficient first-in-human trial models. It also adds context to how sponsors and CROs may retool study start timelines ahead of regulatory review. Together, the developments point to a near-term operational focus: getting studies started faster while keeping oversight and review quality intact.